High-Flow Nasal Cannula in Respiratory Failure: A Perspective Review: High-Flow Cannula for Respiratory Failure

Abstract

Background: High-Flow Nasal Cannula (HFNC) therapy has grown significantly as an alternative non-invasive respiratory support for respiratory insufficiency, both acute and chronic. The treatment entails providing heated and humidified oxygen at high flow rates to enhance oxygenation, minimize anatomical dead space, lower the work of breathing, and increase patient tolerance than conventional oxygen therapy.

Materials and Methods: This narrative review study conducted searches in PubMed and other reputable medical databases to collect literature on the physiological effects, indications, benefits, downsides, and outcomes associated with HFNC for respiratory failure. Data were extracted from randomized trials, observational studies, systematic reviews, and guidelines.

Results: Available evidence suggests that HFNC has significant benefits for treating acute hypoxemic respiratory failure, COPD exacerbations, post-extubation respiratory support, pre-oxygenation for intubation, cardiogenic pulmonary edema, and respiratory insufficiency related to COVID-19. HFNC provides superior oxygenation, secretion removal, respiratory tolerance, and comfort compared to standard oxygen therapy. In selected patients, HFNC may be used to delay or avoid invasive ventilation. Delaying recognition of HFNC failure may impact the prognosis negatively.

Discussion: HFNC is widely recognized because of its physiological superiority and ease of use. HFNC should be carefully selected and continuously monitored, escalating to invasive ventilation early when necessary.

Conclusion: HFNC represents an effective and well-tolerated noninvasive respiratory support strategy, particularly in acute hypoxemic respiratory failure. Appropriate implementation and vigilant monitoring are crucial for maximizing therapeutic benefit and improving patient outcomes.